<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interferon-alpha (IFN-α) has strong antitumor effects, and IFN-α gene therapy has been used clinically against some <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we evaluated the efficacy of the combination of IFN-α-transduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell vaccines and programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> 1 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1) blockade, and investigated the mechanisms of the antitumor effects of the combined therapy </plain></SENT>
<SENT sid="2" pm="."><plain>A poorly immunogenic murine <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell line, MC38, was transduced to overexpress IFN-α </plain></SENT>
<SENT sid="3" pm="."><plain>In a therapeutic model, parental <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice were inoculated with MC38-IFNα cells and an anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 antagonistic antibody </plain></SENT>
<SENT sid="4" pm="."><plain>Analyses of immunohistochemistry and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific lysis were performed </plain></SENT>
<SENT sid="5" pm="."><plain>The outgrowth of the established <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> was significantly reduced in mice treated with the combination of IFN-α and anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 </plain></SENT>
<SENT sid="6" pm="."><plain>Immunohistochemical analyses of the therapeutic model showed marked infiltration of CD4(+) cells and CD8(+) cells in the established MC38 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of mice treated with both IFN-α and anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 </plain></SENT>
<SENT sid="7" pm="."><plain>Significant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific cytolysis was detected when splenocytes of mice that were treated with both IFN-α and anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 were used as effector cells </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that blockade of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 PD-ligand enhanced the Th1-type antitumor immune responses induced by IFN-α </plain></SENT>
<SENT sid="9" pm="."><plain>The combination of IFN-α gene-transduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell vaccines and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 blockade may be a possible candidate for a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccine for clinical trials </plain></SENT>
</text></document>